6126
L. Qiao et al. / Bioorg. Med. Chem. Lett. 19 (2009) 6122–6126
4. Holder, N.; Cooke, J.; Brennan, C. Eur. J. Neurosci. 1998, 10, 405.
5. Willson, C. A.; Foster, R. D.; Onifer, S. M.; Whittemore, S. R.; Miranda, J. D. J. Mol.
Hist. 2006, 37, 369.
6. Liu, X.; Hawkes, E.; Ishimaru, T.; Tran, T.; Sretavan, D. W. J. Neurosci. 2006, 26,
3087.
7. (a) Willson, C. A.; Miranda, J. D.; Foster, R. D.; Onifer, S. M.; Whittemore, S. R.
Cell Transplant. 2003, 12, 279; (b) Miranda, J. D.; White, L. A.; Marcillo, A. E.;
Willson, C. A.; Jagid, J.; Whittemore, S. R. Exp. Neurol. 1999, 156, 218.
8. Farivar, R. S.; Gardner-Thorpe, J.; Ito, H.; Arshad, H.; Zinner, M. J.; Ashley, S. W.;
Whang, E. E. J. Surg. Res. 2003, 115, 219.
9. (a) Kang, J. U.; Koo, S. H.; Kwon, K. C.; Park, J. W.; Kim, J. M. BMC Cancer 2009, 9,
237; (b) Berardi, A. C.; Marsilio, S.; Rofani, C.; Salvucci, O.; Altavista, P.; Perla, F.
M.; Diomedi-Camassei, F.; Uccini, S.; Kokai, G.; Landuzzi, L.; McDowell, H. P.;
Dominici, C. Anticancer Res. 2008, 28, 763.
ture–activity relationship of both heterocyclic series was similar.
However, the imidazo[1,2-a]pyridines offered enhanced in vitro
metabolic stability as assessed in mouse liver microsomes. In par-
ticular, 32 (LDN-211904) was a potent EphB3 inhibitor, displaying
excellent liver microsome stability and had enhanced aqueous sol-
ubility due to incorporation of a more basic secondary amine.
EphB3 inhibitory activity was also demonstrated for representative
analogs in cell culture and a correlation with in vitro biochemical
activity was demonstrated. Finally, 32 was profiled for inhibitory
activity against a panel of kinases and found to be quite selective
for tyrosine kinases. These studies provide useful molecular probes
for examining the in vitro and cellular kinase-dependent function
of EphB3. Continued optimization of this compound series to fur-
ther increase selectivity could afford additional analogs useful for
exploring the in vivo pharmacology of EphB3 kinase inhibition in
various animal disease models where EphB3 receptor expression
occurs, either endogenously or as a result of injury or disease.
10. (a) Miao, H.; Strebhardt, K.; Pasquale, E. B.; Shen, T.-L.; Guan, J.-L.; Wang, B. J.
Biol. Chem. 2005, 280, 923; (b) Kullander, K.; Mather, N. K.; Diella, F.; Dottori,
M.; Boyd, A. W.; Klein, R. Neuron 2001, 29, 73.
11. Binns, K. L.; Taylor, P. P.; Sicheri, F.; Pawson, T.; Holland, S. J. Mol. Cell Biol. 2000,
20, 4791.
12. For an example of small molecules inhibiting ephrin binding to the EphA2 and
EphA4 receptors see: Noberini, R.; Koolpe, M.; Peddibhotla, S.; Dahl, R.; Su, Y.;
Cosford, N. D. P.; Roth, G. P.; Pasquale, E. B. J. Biol. Chem. 2008, 283, 29461.
13. For other Eph receptor kinase inhibitors see: (a) Choi, Y.; Syeda, F.; Walker, J. R.;
Finerty, P. J., Jr.; Cuerrier, D.; Wojciechowski, A.; Liu, Q.; Dhe-Paganon, S.; Gray,
N. S. Bioorg. Med. Chem. Lett. 2009, 19, 4467; (b) Bardelle, C.; Cross, D.;
Davenport, S.; Kettle, J. G.; Ko, E. J.; Leach, A. G.; Mortlock, A.; Read, J.; Roberts,
N. J.; Robins, P.; Williams, E. J. Bioorg. Med. Chem. Lett. 2008, 18, 2776; (c) Kolb,
P.; Kipouros, C. B.; Huang, D.; Caflisch, A. Proteins 2008, 73, 11; (d) Miyazaki, Y.;
Nakano, M.; Sato, H.; Truesdale, A. T.; Stuart, J. D.; Nartey, E. N.; Hightower, K.
E.; Kane-Carson, L. Bioorg. Med. Chem. Lett. 2007, 17, 250; (e) Caligiuri, M.; Molz,
L.; Liu, Q.; Kaplan, F.; Xu, J. P.; Majeti, J. Z.; Ramos-Kelsey, R.; Murthi, K.;
Lievens, S.; Tavernier, J.; Kley, N. Chem. Biol. 2006, 13, 711.
Acknowledgments
The authors thank the Harvard NeuroDiscovery Center for
financial support. This work was also supported in part by an
NIH grant (U24 NS049339). We also would like to thank Dr.
Bing-Cheng Wang (Case Western Reserve University School of
Medicine, Cleveland, OH) for the HEK293 cells expressing wild-
type or kinase-inactive EphB3.
14. See supplementary data for details.
15. Ninomiya, K.; Shioiri, T.; Yamada, S. Tetrahedron 1974, 30, 2009.
16. Tamura, Y.; Minamikawa, J.; Miki, Y.; Matsugashita, S.; Ikeda, M. Tetrahedron
Lett. 1972, 40, 4133.
17. Tamura, Y.; Sumida, Y.; Miki, Y.; Ikeda, M. J. Chem. Soc., Perkin Trans. 1 1975,
406.
18. Coppola, G. M.; Damon, R. E. Synth. Commun. 1993, 23, 2003.
19. Georgescu, F.; Georgescu, E.; Draghici, C.; Iuhas, P. C.; Filip, P. I. Rev. Roumaine
Chim. 2005, 50, 349; Chem. Abstr. 2005, 144, 350628.
Supplementary data
Supplementary data associated with this article can be found, in
20. Mayer, A.; Leumann, C. J. Eur. J. Org. Chem. 2007, 4038.
´
21. Baranczewski, P.; Stanczak, A.; Sundberg, K.; Svensson, R.; Wallin, A.; Jannson,
J.; Garberg, P.; Postlind, H. Pharmacol. Rep. 2006, 58, 453.
22. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.;
Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.;
Floyd, R.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.;
Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. Nat. Biotechnol. 2008,
26, 127.
References and notes
1. Pasquale, E. B. Nat. Rev. Mol. Cell Biol. 2005, 6, 462.
2. Kullander, K.; Klein, R. Nat. Rev. Mol. Cell. Biol. 2002, 3, 475.
3. (a) Pasquale, E. B. Cell 2008, 133, 38; (b) Himanen, J. P.; Saha, N.; Nikolov, D. B.
Curr. Opin. Cell. Biol. 2007, 19, 534; (c) Aoto, J.; Chen, L. Brain Res. 2007, 1184, 72.